Magle Chemoswed Holding AB
STO:MAGLE
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.6
46
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Magle Chemoswed Holding AB
Total Equity
Magle Chemoswed Holding AB
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Magle Chemoswed Holding AB
STO:MAGLE
|
Total Equity
kr158.2m
|
CAGR 3-Years
11%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
AddLife AB
STO:ALIF B
|
Total Equity
kr5B
|
CAGR 3-Years
38%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Total Equity
kr3.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotage AB
STO:BIOT
|
Total Equity
kr3.8B
|
CAGR 3-Years
52%
|
CAGR 5-Years
34%
|
CAGR 10-Years
23%
|
|
|
G
|
Genovis AB
STO:GENO
|
Total Equity
kr207.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
48%
|
CAGR 10-Years
22%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Total Equity
kr1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
17%
|
|
Magle Chemoswed Holding AB
Glance View
Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
See Also
What is Magle Chemoswed Holding AB's Total Equity?
Total Equity
158.2m
SEK
Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Total Equity amounts to 158.2m SEK.
What is Magle Chemoswed Holding AB's Total Equity growth rate?
Total Equity CAGR 5Y
26%
Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Magle Chemoswed Holding AB have been 11% over the past three years , 26% over the past five years .
You don't have any saved screeners yet
